Today on the Daily Dive, our host Cassandra Leah sits down with Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). Ian joins us today to give the two minute elevator pitch for his company, to give his take on what separates the real operators from the pretenders within the psychedelics space, and to discuss the bench strength he has assembled in terms of his management and advisory teams.

Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

The post Bright Minds: The Next Revolution In Mental Health Care – The Daily Dive appeared first on the deep dive.